Home

Primary Examiner: Phillips, Delbert R.
Assistant Examiner:
Attorney: Blanchard, Flynn, Thiel, Boutell & Tanis

Next ten patents ordered by date:

Peptide carbazates and pharmaceutical composition
Synergistic pesticidal mixtures of phosalone and malathion and process for controlling arthropods therewith
Antibiotic composition containing an antibiotic and as a potentiating agent pyrrolidone carboxylic acid or derivative thereof
Halogenated unsaturated alkyl benzenedisulfonamides as anthelmintics
7[(Carboxyoxiran-3-carboxamido)phenylacetamido]cephalosporin derivatives
7-Acylamino-3-[1-(2,3-dihydroxypropyl)tetrazole-5-ylthiomethyl]-3-ceph em-4-carboxylic acids
Heterocyclic-substituted 1,3,5-oxadiazin-2-one compounds useful for combatting coccidiosis
Organic compounds
N-Phenoxyphenyl-piperazines
Hydroxymethyl-substituted-2(1H)-quinazolinones

Translate:
En
De
Es
Fr
It
Pt
Ja
Ko
Zh

Title: Dopamine derivative compounds, preparation thereof and medicine containing same

Do you think this is a good invention? Vote now:

Votes so far: For:(0) Against:(0)
Claims: The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. A compound having the formula: ##STR8## wherein X is a di- or tri-peptide residue derived from alanine, glycine, glutamine, isoleucine, lysine, leucine, tyrosine, proline or valine, or a pharmacologically acceptable acid addition salt thereof.

2. A compound as claimed in claim 1 wherein the group ##STR9## is a glycyl-L-prolyl group.

3. A compound as claimed in claim 1 wherein the group ##STR10## is a L-isoleucylvalyl group.

4. A compound as claimed in claim 1 wherein the group ##STR11## is a glycyl-L-glutamyl group.

5. A compound as claimed in claim 1 wherein the group ##STR12## is a glycylglycyl-L-Leucyl group.

6. A compound as claimed in claim 1 wherein the group ##STR13## is a glycylglycyl-L-prolyl group.

7. A method of increasing the renal blood flow rate in a subject requiring such treament, which comprises: administering to such subject a therapeutically effective amount of a compound having the formula: ##STR14## wherein X is a di- or tri-peptide residue derived from alanine, glycine, glutamine, isoleucine, lysine, leucine, tyrosine, proline or valine,

or a pharmacologically acceptable acid addition salt thereof.

8. A method as claimed in claim 7 wherein the group ##STR15## is a glycyl-L-prolyl group.

9. A method as claimed in claim 7 wherein the group ##STR16## is an L-isoleucylvalyl group.

10. A method as claimed in claim 7 wherein the group ##STR17## is a glycyl-L-glutamyl group.

11. A method as claimed in claim 7 wherein the group ##STR18## is a glycylglycyl-L-leucyl group.

12. A method as claimed in claim 7 wherein the group ##STR19## is a glycylglycyl-L-prolyl group.

13. A method according to claim 7 in which said compound is administered in combination with a pharmaceutical carrier.

14. A method according to claim 7 in which the compound is administered in an amount of from 10 to 500 mg per day.
Other info:

Inventors: Yanaihara, Noboru (Shizuoka, JA)
Igarashi, Toshiji (Tokorozawa, JA)
Kunii, Youichi (Funabashi, JA)

Application Number: 715008
Filing Date: 1976-08-17
Publication_date: 1977-12-20
Assignee: Eisai Co., Ltd. (Tokyo, JA)
Primary Class(es): 514/19 260/1, 514/18, 530/331
Other Classes:
US Patent Ref:

3803120

Apr, 1974

Felix

424/177.

Other Refs: Other References: Jones et al.; Am. Chem. Soc., 165, Meet. Medi. 11, 1973.
John L. McNay et al.; Chem. Abst. 63, 1965, p. 8916g.
Sandler et al.; Prog. Med. Chem. 6, 200, 1969.
D. B. Calne et al.; Nature 226, 1970, pp. 21-24.